by Oncospherix | May 13, 2025 | General
May 13, 2025 Emerging oncology innovator OncoSpherix to showcase breakthrough cancer therapies at global biotech stage in Boston Atlanta, GA — May 2025 — OncoSpherix, a pre-clinical-stage oncology company advancing novel therapies for unresectable and metastatic...
by Oncospherix | Apr 22, 2025 | General
April 22, 2024 OncoSpherix to Showcase Breakthrough Oncology Innovations at Premier Biotech Event Atlanta, GA – Apr 2025 – OncoSpherix, a biotech company pioneering innovative therapies for tumor hypoxia, is excited to announce its participation in Portal Innovations’...
by Oncospherix | Nov 20, 2024 | General
November 20, 2024 OncoSpherix Becomes a Portal Innovations Member Company Atlanta, GA – Nov 2023 – OncoSpherix,, Inc., a preclinical-stage cancer drug development company advancing HIF inhibitors for a variety of cancer indications, is excited to announce its recent...
by Oncospherix | Nov 18, 2024 | General
November 18, 2024 OncoSpherix Participates in Annual Georgia Life Sciences Summit Atlanta, GA – Nov 18, 2024 – OncoSpherix, Inc., a preclinical-stage cancer drug development company advancing HIF inhibitors for a variety of cancer indications, proudly participated in...
by Oncospherix | Oct 1, 2024 | General
Oct 1, 2024 Joseph Ellis, Ph.D., joins OncoSpherix’s Research Team Atlanta, GA – Oct 1, 2024 – OncoSpherix, Inc., a preclinical-stage cancer drug development company advancing HIF inhibitors in variety of cancer indications, announces the appointment of Joseph Ellis,...
by Oncospherix | Oct 16, 2023 | General
October 16, 2023 Atlanta, GA – October 16, 2023 – The CEO of OncoSpherix, Inc, Dr. Margaret K. Offermann, MD, PhD, is delivering a keynote address at Biopharma Drug Discovery Nexus East Coast 2023 in Philadelphia on Wednesday, October 18 at 9:45 AM. Her presentation...
